Answer
Persistent antibodies against natalizumab are associated with substantially decreased Tysabri efficacy and an increased incidence of hypersensitivity reactions.
Sources for this answer
- TYSABRI 300 mg concentrate for solution for infusionBiogen Idec Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 43Document updated
Sources checked